Role of melanocortin receptors in the regulation of gouty inflammation

Current Rheumatology Reports

Volumn 13, Issue 2, 2011, Pages 138-145

  Montero Melendez, Trinidad ^a   Patel, Hetal B ^a   Perretti, Mauro ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

ACTH; Animal models; Anti inflammatory therapeutics; Clinical development; Drug discovery; G protein coupled receptor; Gout; Inflammation; Inflammatory arthritis; Interleukin 1; Macrophage; MC1; MC3; MC5; Melanocortin receptor 3; Melanocyte stimulating hormone; Neutrophil recruitment; Receptor agonists; Urate inflammation

Indexed keywords

AFAMELANOTIDE; ALLOPURINOL; ALPHA INTERMEDIN; BETA INTERMEDIN; CKPV2; COLCHICINE; CORTICOTROPIN; DEXTRO 8 TRYPTOPHAN GAMMA INTERMEDIN; FEBUXOSTAT; GAMMA INTERMEDIN; HP 228; INTERLEUKIN 1; KPV; MELANOCORTIN; MELANOCORTIN RECEPTOR; MELANOCORTIN RECEPTOR AGONIST; MELANOTAN II; N ACETYL ALPHA INTERMEDIN[4-10]CYCLO[4 NORLEUCINE 5 ASPARTIC ACID 7 [3 (2 NAPHTHYL)ALANINE] 10 LYSINAMIDE]; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; RILONACEPT; UNCLASSIFIED DRUG; URATE;

ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; DRUG MECHANISM; GOUT; HUMAN; IMMUNOMODULATION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RECEPTOR BINDING; REGULATORY MECHANISM;

ALLOPURINOL; ANIMALS; ARTHRITIS, GOUTY; COLCHICINE; CRYSTALLIZATION; DISEASE MODELS, ANIMAL; GOUT SUPPRESSANTS; HUMANS; INJECTIONS, INTRA-ARTICULAR; MELANOCORTINS; MICE; RECEPTORS, MELANOCORTIN; URIC ACID;

EID: 79957477590     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-011-0163-0     Document Type: Article

References (46)

1. R Terkeltaub 2010 Update on gout: new therapeutic strategies and options Nat Rev Rheumatol 6 30 38 20046204 10.1038/nrrheum.2009.236 1:CAS:528: DC%2BC3cXotlSi This is an excellent state-of-the-art review that covers the pathogenesis of gout as well as therapeutic options. Updated to include the latest developments, it is a must read for experts as well as novices in the area
2. RC Landis DO Haskard 2001 Pathogenesis of crystal-induced inflammation Curr Rheumatol Rep 3 36 41 11177769 10.1007/s11926-001-0049-7 1:STN:280:DC%2BD38%2Fgs1yksQ%3D%3D
3. HR Schumacher Jr, et al. 2008 Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial Arthritis Rheum 59 1540 1548 18975369 10.1002/art.24209 1:CAS:528:DC%2BC3cXpvFyhtLs%3D
4. HN Leopold 1950 ACTH and colchicine in therapy of gout; report of a case of acute gouty arthritis Tex State J Med 46 710 712 14776711 1:STN:280:DyaG3M%2Fgs1alsw%3D%3D
5. RA Terkeltaub, et al. 2010 High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study Arthritis Rheum 62 1060 1068 20131255 10.1002/art.27327 1:CAS:528:DC%2BC3cXhtFGnu7rE This is an important clinical study that validates the use of low-dose colchicine in gout, observing significant disease control with a much lower burden of side effects. The conclusion reached in the study may have direct implications for the management of disease among many gouty patients
6. RJ Flower 2003 The development of COX2 inhibitors Nat Rev Drug Discov 2 179 191 12612644 10.1038/nrd1034 1:CAS:528:DC%2BD3sXhsFKrtLg%3D (Pubitemid 37361663)
7. HJ Janssens, et al. 2008 Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial Lancet 371 1854 1860 18514729 10.1016/S0140-6736(08)60799-0 1:CAS:528: DC%2BD1cXmsFKntr4%3D (Pubitemid 351736009)
8. JL Wallace, et al. 2009 Cyclooxygenase-inhibiting nitric oxide donators for osteoarthritis Trends Pharmacol Sci 30 112 117 19230986 10.1016/j.tips.2009. 01.001 1:CAS:528:DC%2BD1MXivVGgtbk%3D This is a state-of-the art review on the development of novel anti-inflammatory therapeutics, with emphasis on the lower degree of side effects they cause, as well as on the efficacy in joint disease. These compounds could be useful for the control of gout
9. JL Wallace, et al. 2010 Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346) Br J Pharmacol 159 1236 1246 20128814 10.1111/j.1476-5381.2009.00611.x 1:CAS:528:DC%2BC3cXjs1ektb8%3D This was an important study on a novel anti-inflammatory derivative of naproxen, based on the controlled release of hydrogen sulfide, that could lead to a new class of therapeutics
10. F Martinon, et al. 2006 Gout-associated uric acid crystals activate the NALP3 inflammasome Nature 440 237 241 16407889 10.1038/nature04516 1:CAS:528:DC%2BD28XitFGitLg%3D (Pubitemid 43372104)
11. R Terkeltaub, et al. 2009 The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study Ann Rheum Dis 68 1613 1617 19635719 10.1136/ard.2009.108936 1:STN:280:DC%2BD1MnhslOruw%3D%3D This fundamental clinical investigation supports the pivotal role played by IL-1 in gout. This would open the door to other strategies aiming at blockade of release and/or effects of this cytokine
12. PS Hench, et al. 1949 The effect of the adrenal cortex (17-hydroxy-11-dehydrocortisone: compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis; preliminary report Proc Staff Meet Mayo Clin 24 181 197 1:CAS:528:DyaG3cXitVyiug%3D%3D
13. AB Gutman TF Yu 1950 Effects of adrenocorticotropic hormone (ACTH) in gout Am J Med 9 24 30 15425530 10.1016/0002-9343(50)90004-0 1:STN:280: DyaG3c%2FjsFWlsA%3D%3D
14. N Schlesinger 2008 Overview of the management of acute gout and the role of adrenocorticotropic hormone Drugs 68 407 415 18318560 10.2165/00003495- 200868040-00002 1:CAS:528:DC%2BD1cXmtFKlurs%3D This is an excellent review on the application of ACTH in gout. There is more to this hormone that could be exploited for novel antigout approaches. It is highly relevant to the topic of this article (Pubitemid 351342012)
15. J Ritter, et al. 1994 ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems J Rheumatol 21 696 699 8035395 1:STN:280:DyaK2czgvFSgtA%3D%3D (Pubitemid 24126767)
16. T Brzoska, et al. 2008 Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases Endocr Rev 29 581 602 18612139 10.1210/er.2007-0027 1:CAS:528:DC%2BD1cXhtVKnsrjM This is a detailed and competent review on the MC pathway, summarizing biochemical synthesis, biological properties, and therapeutic potential. It is an updated summary on the anti-inflammatory and tissue-protective properties of MC peptides
17. I Gantz TM Fong 2003 The melanocortin system Am J Physiol Endocrinol Metab 284 E468 E474 12556347 1:CAS:528:DC%2BD3sXisFegtLs%3D
18. SK Manna BB Aggarwal 1998 Alpha-melanocyte-stimulating hormone inhibits the nuclear transcription factor NF-kappa B activation induced by various inflammatory agents J Immunol 161 2873 2880 9743348 1:CAS:528:DyaK1cXmtVKnsbk%3D (Pubitemid 28425709)
19. Eves PC, Haycock JW. Melanocortin signalling mechanisms. In: Catania A, editor. Melanocortins Multiple actions and therapeutic potential Landes Bioscience, 2009. p. 19-27.
20. SJ Getting, et al. 2002 Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis Arthritis Rheum 46 2765 2775 12384937 10.1002/art.10526 1:CAS:528: DC%2BD38XovVWitbw%3D (Pubitemid 36118942)
21. SJ Getting, et al. 2009 Melanocortin peptide therapy for the treatment of arthritic pathologies ScientificWorldJournal 9 1394 1414 20024514 1:CAS:528:DC%2BC3cXhtl2qtL8%3D This review states the potential for therapeutics based on the MC system for pathologies of the joint, including gout. It is an excellent summary
22. AS Chen, et al. 2000 Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass Nat Genet 26 97 102 10973258 10.1038/79254 1:CAS:528:DC%2BD3cXmsVKrsrw%3D
23. 3 in the context of experimental joint disease. Data presented here also reveal novel properties for ligands to this receptor in the context of osteoclast generation
24. I Gantz, et al. 1993 Molecular cloning of a novel melanocortin receptor J Biol Chem 268 8246 8250 8463333 1:CAS:528:DyaK3sXksVWitbs%3D (Pubitemid 23120413)
25. W Chen, et al. 1997 Exocrine gland dysfunction in MC5-R-deficient mice: evidence for coordinated regulation of exocrine gland function by melanocortin peptides Cell 91 789 798 9413988 10.1016/S0092-8674(00)80467-5 1:CAS:528:DyaK2sXotV2itbs%3D (Pubitemid 28007735)
26. AW Taylor, et al. 2006 Melanocortin 5 receptor and ocular immunity Cell Mol Biol (Noisy-le-grand) 52 53 59 1:CAS:528:DC%2BD28XmsFeruro%3D (Pubitemid 43989248)
27. • Patel HB, et al. Melanocortin control of cell trafficking in vascular inflammation. In: Catania A, editor. Melanocortins: Multiple actions and therapeutic potential Landes Bioscience, 2009. p. 88-102. This is a summary of the pharmacology of MC receptors and their agonists in experimental models of inflammation and tissue injury. It also covers some of the efforts produced by Biotech and pharmaceutical companies to develop novel therapeutics based on this line of research.
28. A Matsukawa, et al. 1998 Analysis of the cytokine network among tumor necrosis factor alpha, interleukin-1beta, interleukin-8, and interleukin-1 receptor antagonist in monosodium urate crystal-induced rabbit arthritis Lab Invest 78 559 569 9605181 1:CAS:528:DyaK1cXjs12kt7s%3D (Pubitemid 28246980)
29. Cronstein BN, Terkeltaub R. The inflammatory process of gout and its treatment. Arthritis Res Ther 2006;8 Suppl 1:S3.
30. R Liu-Bryan 2010 Intracellular innate immunity in gouty arthritis: role of NALP3 inflammasome Immunol Cell Biol 88 20 23 19935768 10.1038/icb.2009.93 1:CAS:528:DC%2BC3cXhvFWmtg%3D%3D This important article summarizes the importance of the inflammasome in gouty arthritis. Important links with autoinflammatory disease can be derived, sharing also IL-1 blockade as an efficient strategy for innovative therapy
31. Y Shi, et al. 2010 Monosodium urate crystals in inflammation and immunity Immunol Rev 233 203 217 20193001 10.1111/j.0105-2896.2009.00851.x 1:CAS:528:DC%2BC3cXjslaru7k%3D This is a competent and well-written review that presents an updated summary on the pathology of gout, including the intracellular events associated with the inflammasome
32. HM Hoffman, et al. 2010 Role of the leucine-rich repeat domain of cryopyrin/NALP3 in monosodium urate crystal-induced inflammation in mice Arthritis Rheum 62 2170 2179 20506351 1:CAS:528:DC%2BC3cXht1aqsL3L In this elegant article, cryopyrin leucine-rich repeat deletion mutant mice are generated to highlight the essential requirement of the leucine-rich domain for caspase-1 activation and IL-1β release in macrophages
33. DR Yagnik, et al. 2004 Macrophage release of transforming growth factor beta1 during resolution of monosodium urate monohydrate crystal-induced inflammation Arthritis Rheum 50 2273 2280 15248227 10.1002/art.20317 1:CAS:528:DC%2BD2cXmsVantr4%3D (Pubitemid 38924406)
34. SJ Getting, et al. 1999 POMC gene-derived peptides activate melanocortin type 3 receptor on murine macrophages, suppress cytokine release, and inhibit neutrophil migration in acute experimental inflammation J Immunol 162 7446 7453 10358199 1:CAS:528:DyaK1MXktFersLk%3D (Pubitemid 29277724)
35. R Terkeltaub, et al. 1998 The murine homolog of the interleukin-8 receptor CXCR-2 is essential for the occurrence of neutrophilic inflammation in the air pouch model of acute urate crystal-induced gouty synovitis Arthritis Rheum 41 900 909 9588743 10.1002/1529-0131(199805)41:5<900::AID-ART18>3.0. CO;2-K 1:CAS:528:DyaK1cXjtlSjurY%3D (Pubitemid 28225791)
36. S Grassel, et al. 2009 The melanocortin system in articular chondrocytes: melanocortin receptors, pro-opiomelanocortin, precursor proteases, and a regulatory effect of alpha-melanocyte-stimulating hormone on proinflammatory cytokines and extracellular matrix components Arthritis Rheum 60 3017 3027 19790046 10.1002/art.24846 This was a fundamental study demonstrating MC functions in chondrocytes; description of receptor expression is complemented by in vitro analyses of anabolic effects upon MC peptide addition to human chondrocytes
37. J Cornish, et al. 2003 alpha-melanocyte-stimulating hormone is a novel regulator of bone Am J Physiol Endocrinol Metab 284 E1181 E1190 12618359 1:CAS:528:DC%2BD3sXltVegt7c%3D
38. R Torres, et al. 2009 Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by interleukin 1 inhibition in a novel animal model of gouty arthritis Ann Rheum Dis 68 1602 1608 19528034 10.1136/ard.2009.109355 1:CAS:528:DC%2BD1MXhtlKqtbbM This was an important preclinical study assessing the pathogenic pathways activated by urate crystals to promote inflammatory disease
39. SJ Getting, et al. 2003 Redundancy of a functional melanocortin 1 receptor in the anti-inflammatory actions of melanocortin peptides: studies in the recessive yellow (e/e) mouse suggest an important role for melanocortin 3 receptor J Immunol 170 3323 3330 12626592 1:CAS:528:DC%2BD3sXhslOrtrc%3D (Pubitemid 36302211)
40. F Capsoni, et al. 2009 Melanocortin peptides inhibit urate crystal-induced activation of phagocytic cells Arthritis Res Ther 11 R151 19814819 10.1186/ar2827 The findings of this study illustrate the inhibitory activity of MC peptides on monocyte production of chemotactic factors and subsequent neutrophil responses to these chemotactic factors in MSU crystal-induced inflammation
41. SJ Getting, et al. 2001 Natural and synthetic agonists of the melanocortin receptor type 3 possess anti-inflammatory properties J Leukoc Biol 69 98 104 11200074 1:CAS:528:DC%2BD3MXlvFChsQ%3D%3D (Pubitemid 32095123)
42. SJ Getting, et al. 2006 [D-Trp8]-gamma-melanocyte-stimulating hormone exhibits anti-inflammatory efficacy in mice bearing a nonfunctional MC1R (recessive yellow e/e mouse) Mol Pharmacol 70 1850 1855 16959942 10.1124/mol.106.028878 1:CAS:528:DC%2BD28Xht1ylt73J (Pubitemid 44771900)
43. SJ Getting, et al. 2006 Melanocortin 3 receptors control crystal-induced inflammation FASEB J 20 2234 2241 17077300 10.1096/fj.06-6339com 1:CAS:528:DC%2BD28XhtFyktLfI (Pubitemid 44953853)
44. G Leoni, et al. 2008 Inflamed phenotype of the mesenteric microcirculation of melanocortin type 3 receptor-null mice after ischemia-reperfusion Faseb J 22 4228 4238 18757499 10.1096/fj.08-113886 1:CAS:528:DC%2BD1cXhsVKgu7%2FP
45. SJ Getting, et al. 2006 The melanocortin peptide HP228 displays protective effects in acute models of inflammation and organ damage Eur J Pharmacol 532 138 144 16442098 10.1016/j.ejphar.2005.12.023 1:CAS:528: DC%2BD28XhvVWlsbg%3D
46. SJ Getting, et al. 2003 Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides J Pharmacol Exp Ther 306 631 637 12750433 10.1124/jpet.103.051623 1:CAS:528:DC%2BD3sXlslGluro%3D (Pubitemid 36886162)